Burrill Conferences

Sponsors

Presented withGold SponsorSilverBronzeEvent Partners

Life Sciences Conferences

The Indiana Life Sciences Forum

Featured Speakers

G. Steven Burrill
Chief Executive Officer
Burrill & Company

One Embarcaderco Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry
for over 40 years. Mr. Burrill is one of the original architects of the industry. He serves as
Chairman of the Boards of Pharmasset and BioImagene, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed, Intranasal, Phytomedics, ProteoGenix, Proventys, Targacept and XDx. Before founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing services to clients in biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder and Chairman of the Board of the Foundation for the National Medals of Science and Technology. He serves as Chairman of the Board of the Campaign for Medical Research and as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). He serves on the Boards of Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, University of Maryland Biotechnology Institute, MIT Center for Biomedical Innovation, Kramden Institute, and National Health Museum. He serves on the Purdue Discovery Park External Advisory Committee and on the editorial board of the Journal of Commercial Biotechnology. He is an advisor to the University of Illinois Institute for Genomic Biology, University of Wisconsin - College of Agriculture and Life Sciences, Carnegie Mellon, Duke University, and is an adjunct professor at University of California, San Francisco.




Art Pappas
Managing Partner
Pappas Ventures

PO Box 110287
Research Triangle Park, NC
(919) 998-3300
www.pappasventures.com

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts who manage over $250 million and oversee investments in more than 40 portfolio companies. Prior to founding Pappas Ventures in 1994, Art held senior level leadership positions at several multinational pharmaceutical companies. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was the chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Among the companies for which he currently serves as a director are: Genstruct, LEAD Therapeutics and TyRx Pharma. He was the founding CEO and is currently the chairman of CoLucid Pharmaceuticals.

Some of the firm’s representative investments include Cerexa Pharmaceuticals (acquired by Forest Laboratories); Syntonix Pharmaceuticals (acquired by Biogen Idec); Peninsula Pharmaceuticals (acquired by Johnson & Johnson); Panacos Pharmaceuticals (Nasdaq: PANC); NuVasive (Nasdaq: NUVA); Gene Logic (Nasdaq: GLGC); Nuvelo (Nasdaq: NUVO; previously Variagenics); and Arena Pharmaceuticals (Nasdaq: ARNA).

Art is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board.  He previously served on the boards of AtheroGenics (Nasdaq: AGIX), Embrex (Nasdaq: EMBX), Quintiles Transnational (Nasdaq: QTRN) and Valentis (Nasdaq: VLTS).  Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and the Special Forces. 

Education
Ohio State University (BS in Biology)
Xavier University (MBA in Finance)




Elizabeth Camp
Managing Director
HealthpointCapital

505 Park Ave, 12th Fl
New York, NY 10022
(212) 810-4715
www.healthpointcapital.com

Two years at HEALTHPOINTCAPITAL. Ms. Camp has had 22 years’ experience in the private equity industry, investing over $700 million in equity capital.  Previously, she was at Ewing Management Group, where she headed the Business Engagement Team.  Prior to that, she was at Goldman Sachs for seven years, where she managed $11 billion as a Managing Director in the Private Equity Group.  Before joining Goldman Sachs in 1997, Ms. Camp was a General Partner at Gibbons, Green, van Amerongen, one of the industry’s pioneering firms, where she worked for 11 years.  Ms. Camp was previously at Morgan Stanley, in the Mergers and Acquisitions and Capital Markets departments.  Ms. Camp has served on the boards of Fountain View Inc., Rival Manufacturing, Bath Iron Works, Wells Aluminum Corporation and Ladish Company, Inc., as well as on the advisory board of 22 private equity funds.  She is a member of the Board of Youth, I.N.C. and Brooklyn Prospect Charter School.  Ms. Camp received a B.A. from Williams College, from which she graduated Phi Beta Kappa, and an M.B.A. from the Yale School of Management.




Bryan Dunnivant
Managing Director
Lilly Asian Ventures

Eli Lilly and Company
Lilly Corporate Center
Indianapolis IN
46285
www.Lilly.com

Mr. Dunnivant has more than 25 years experience in the biopharmaceutical industry and has held leadership positions across a wide range of functional areas including finance, strategy, R&D, international operations, new business development, and venture investing. He is currently a Managing Director for the $100 million Lilly Asian Ventures fund which he co-founded in 2006.  In addition he has led investments in HemaQuest Pharmaceuticals (and now serves as the company's board chairman), CITIC Pharmaceuticals in China, and Intradigm Corporation and currently represents Lilly Ventures on the board of portfolio companies Bayhill Therapeutics, Protagonist Therapeutics, and MedManage Systems. Prior to joining Lilly Ventures, he was Chief Operating Officer for e.Lilly, a division of Lilly focused on innovation, new business models, and spinning out new technologies and companies. During his tenure at e.Lilly, Mr. Dunnivant was involved in the founding, startup, incubation, and initial financing of several new life science companies. Mr. Dunnivant received his Bachelors of Science in Chemical Engineering from the University of Illinois, and a Masters of Business Administration from Butler University




David Johnson
President & Chief Executive Officer
Biocrossroads

300 N. Meridian St. Suite 950
Indianapolis, IN 46204
(317) 238-2450
www.biocrossroads.com

David Johnson is the President and Chief Executive Officer of BioCrossroads, a market-driven collaboration of Indiana's corporate, university, government and entrepreneurial leaders in the life sciences industry. BioCrossroads supports life sciences development activities by raising investment funds, investing and launching new life sciences businesses, and building innovative business and university collaborations such as the Fairbanks Institute for Healthy Communities, Indiana Health Information Exchange and BioCrossroadsLINX. A longtime business leader and lawyer, Johnson initially served as volunteer chair of BioCrossroads' capital formation task force.  The task force ultimately formed the $73 million Indiana Future Fund I to provide early stage venture capital to emerging Indiana life sciences companies. Johnson also manages the $6 million Indiana Seed Fund I, designed to invest in Indiana life sciences businesses in the earliest stages of growth. An honors graduate of Harvard University, Harvard Law School and Oxford University, where he studied as a Rhodes Scholar, Johnson was a partner in the law firm of Baker & Daniels from 1986 through 2004, and remains "of counsel" with the firm.  He is active on a wide variety of business and community boards.




Joe Muldoon
Chief Executive Officer
FAST

Joe Muldoon leverages over twenty years of experience, building teams to deliver extraordinary results. His leadership experience spans a diverse range of industries and stages, from venture backed start-up to publicly-traded multi-national.

Joe is currently CEO of FAST, a company commercializing core technology developed within Indiana University School of Medicine.  FAST’s first product will be a revolutionary kidney function test that will fill a large and unmet need in healthcare in the diagnosis and treatment of acute kidney injury. Acute kidney injury has high mortality rates and a growing global prevalence. FAST’s advanced tool is vastly superior to current standards in the areas of precision, sensitivity and rapid assessment.

Joe has been active as an advisor for dozens of Midwest entrepreneurs, occasionally serving as acting CEO and Angel investor.

Previously, Joe was President and CEO of FirstMile Technologies, a venture capital backed, bundled broadband services provider.  Prior to that, he served as President of Brightpoint North America, a $750M publicly-traded wireless phone and data equipment logistical services provider that grew four fold under his leadership.  Joe previously held executive management positions at MacMillan Publishing and Olinger.  He started his career as a CPA in Ernst & Young’s Entrepreneurial Services practice.

Joe has a Bachelor of Science in Business from Indiana University’s Kelley School of Business, where he serves as a panelist and speaker for various MBA programs. Active on the boards of several for profit companies, he also serves on the board of The Venture Club of Indiana and Jameson Camp, a not-for profit organization that serves Indiana youth.




Timothy F. Parshall
Founder
Pivotal Strategies


Tim is the founder of Pivotal Strategies—a strategic marketing and business development organization based in Indianapolis, IN.  His experience spans over 25 years in global healthcare strategy, marketing and business development.

Tim has been a Director of Strategic Marketing at both Guidant and Eli Lilly & Company.  He led product marketing and technology acquisition efforts on a national and international level.   Tim’s current focus is on the development of start-up and early-stage revenue companies in both the medical device and biotechnology fields.  He has been a guest university lecturer speaking on the role of licensing and marketing in product development.  Tim is currently on the Board of Directors for Performance Health Technologies, a publicly listed company.  

Tim has a Bachelor in Pharmacy from the University of Sydney and a Master of Business Administration from the University of New South Wales, Australia. 




Dan Peterson
Vice President, Industry & Government Affairs for Cook Group Incorporated
Cook

750 Daniels Way
P.O. Box 489
Bloomington, IN 47402
(812) 339-2235
www.cookgroup.com

Dan Peterson is Vice President, Industry & Government Affairs for Cook Group Incorporated based in Bloomington, IN.  Since joining Cook in 1989, Dan has had management and executive level responsibilities in the areas of operations, finance/accounting, human resources and benefits.  His current responsibilities include oversight of industry, government and external relations.   His primary areas of focus are centered on healthcare policy and delivery, education and workforce development.

His education includes a BS in Biology from Indiana University (1984) and an MBA in Finance also from Indiana University (1989).

His current board responsibilities include:

• US Department of Commerce Industry Trade Advisory Committee
• Medical Technology Leadership Forum Board of Directors
• BioCrossroads Board of Directors
• Indiana Health Industry Forum Board of Directors – Chairman (2007-2008)
• Indiana Manufacturer’s Association Board of Directors
• Indiana Fiscal Policy Institute Board of Directors
• Indiana University College of Arts & Sciences Alumni Board of Directors
• Indiana University P-16 Center Advisory Board
• Ivy Tech Community College Bloomington – Board of Trustees
• Bloomington Hospital Board of Directors – Chairman (2008-2009)
• Bloomington Life Sciences Partnership Executive Committee - Chairman
• Bloomington Economic Development Corporation Board of Directors – Executive Committee
• Foundation of Monroe County Community Schools Board of Directors

Since 1963, Cook Group companies have been among the leaders in developing health care devices that have improved lives around the world.  Cook has been at the forefront of medical research and product development in Interventional Radiology/Cardiology, Endovascular Medicine, Urology, Women’s Health, GI/Endoscopy, Surgery, Critical Care Medicine and other growing diagnostic and therapeutic practices.




John Barnard
Managing Director
Pearl Street Venture Funds

20 N. Meridian St., Suite 801
Indianapolis, IN 46204
United States
317-684-3719
www.psvf.com

Mr. John Barnard is the Founder of Barnard Associates, Inc. (1994) and Barnard Life Sciences (2001). He has 27 years of financial experience at Eli Lilly and Company including Controller of International Operations, Director of Financial Systems, Director of Business Process Reengineering and Controller of DowElanco. Business restructuring experience includes the sale of Elizabeth Arden to Faberge, the creation of DowElanco, Lilly joint ventures in Brazil and Japan, and the formation of numerous other new ventures. Since 1994, John has assisted in the founding of more than a dozen new firms as well as the capitalization and acceleration of many more. John currently serves on the board of several entrepreneurial growth companies including Progeny LMS, LLC; Your Encore, Inc. and NNC Group, LLC. He has a BA degree in Psychology from Hanover College, Hanover, Indiana and a MBA degree from Butler University, Indianapolis, Indiana.




Dick Aderman
President & Chief Executive Officer
Quadraspec

3000 Kent Ave.
West Lafayette, IN 47906
(765) 775-1026
www.quadraspec.com

Dick Aderman has an extensive background in diagnostics and healthcare. From 1980 through 1996 he held various positions in sales, marketing and general management with American Hospital Supply Corporation, Baxter Healthcare and Dade International. Nearly all his time there was in the laboratory diagnostics business where he established a track record of successful results with product line turnarounds, new product launches and product line growth strategies.
From 1997 through mid-2005, Dick was a member of senior management at Boehringer Mannheim later acquired by Roche Diagnostics. There he lead in the explosive growth of Roche through his leadership in Corporate Accounts, amassing an impressive record of successful contract negotiations  in GPO’s and IHN’s resulting in double digit growth for Roche Diagnostics.
He was appointed to Sr. VP and GM for the Centralized and Molecular Lab businesses in 2000. Here he led his team to a dramatic turned around through the implementation of a strong vision and the implementation of five key strategies. Amongst those, was the implementation of a focused customer marketing method, Six Sigma for process excellence, the Roche customer experience, the leadership through employee enrichment and innovation for growth. These actions resulted in annual sales growth of over 11% and dramatic profit growth  during a 5 year period. 
During this time period, Roche Diagnostics became the number one diagnostics company in the U.S. and achieved the top ranking in customer satisfaction. Roche also was named to the Top 100 Best Places to Work list by Fortune Magazine. They were also recognized by Frost and Sullivan as the leader for innovation with on-line services and connectivity solutions for customers.
From mid-2005 until present, Dick has been involved with early and mid-stage start-ups in disease management software, medical devices and marketing consulting. He joined Quadraspec’s Board of Directors in December of 2006 and joined the executive leadership team as President and Chief Operating Officer in September of 2007. Quadraspec is growing through it’s partnership agreements in the veterinary testing market and is pursuing agreements in life sciences and clinical diagnostics.
He also serves as Chairman of the Board for the American Heart Association of Indianapolis.
He is a 1979 graduate of Western Michigan University in Kalamazoo, MI where he earned degrees in business administration (BBA) and speech communications (BS).




John Hamer, Ph.D.
Managing Director
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
www.burrillandco.com

John E. Hamer serves as a Managing Director at Burrill and Co., a life science merchant bank in San Francisco, specializing in venture investment and strategic partnering for Life Science companies.  Dr. Hamer brings over 20 years of research, business development and operational management experience to Burrill and Company.  He initially came to Burrill as an Entrepreneur-In-Residence in 2003.  During this time he founded and served as President/CEO of Arête Therapeutics Inc. a privately held drug-development company focusing on developing new therapeutics for cardiovascular diseases and inflammation.  While at Burrill, Dr. Hamer lead Arete Therapeutics Inc. through its start-up phase of licensing its core technology, building its early management and science team and securing a $16M Series A investment by a world class syndicate.  Prior to joining Burrill & Company, Dr. Hamer served as Research Director (1998) and CSO (1999-2003) and interim CEO (2002) for ICORIA (now Clinical Data Inc. Nasdaq: CLDA) .

Dr Hamer received his Ph.D. in Microbiology from the University of California, Davis in 1987 and was a Visiting Scientist at Dupont’s Central Research and Development from 1987 to 1989. Dr.  Hamer joined the faculty of Purdue University where he held positions of Assistant Professor (‘89-‘92), Associate Professor (‘92-‘98) and Professor (‘98-‘00) and is currently an Honorary Adjunct Professor of Biological Sciences. Dr. Hamer also served as Adjunct Professor of Microbiology and Immunology at Indiana University/Purdue University Medical School. Dr. Hamer has received numerous grants and awards of distinctions throughout his career including a David and Lucille Packard Fellowship (1990-1995) and the National Science Foundation Presidential Faculty Fellowship (1993-1998). Dr. Hamer has served on numerous scientific review and advisory boards including those for the National Institutes of Health, the National Science Foundation, Purdue Alumni Science Advisory Board and the North Carolina Genomic and Bioinformatics Consortium.  He currently serves on the Corporate Boards for Chromatin (Chairman); Osprey Pharmaceuticals (Chairman), Nanovasc,  Nucleonics and Cobalt Biofuels. Dr Hamer works closely with entrepreneurs to guide early stage investments in biotechnology.

 




Matthew K. Hudes
US Managing Principal, Biotechnology
Deloitte

50 Fremont St.
San Francisco, CA
94105
415 783-6161
www.deloitte.com

Matthew Hudes is U.S. Managing Principal, Biotechnology, for Deloitte’s Life Sciences & Health Care practice.  In this role, he develops, provides and leads the practice’s professional services, working with Tax, Audit, Consulting, and Financial Advisory Services, for this dynamic industry sector.  Previously, he was the Chairman and CEO of Accélère, a software company that developed a system to find patients (and investigators) for clinical trials and to improve researchers’ access to information typically “trapped” in laboratory and medical systems.

Matthew has provided strategic professional services to leading biotechnology and pharmaceutical companies, including Amgen, Amylin, Biogen Idec, Chiron, Genentech, Gilead, Johnson & Johnson, and Sanofi-Aventis.  He speaks frequently about topics such as the use of technology for innovating clinical research, manufacturing and quality, regulatory compliance, and supply chain.

Formerly, Matthew led the global Capgemini Life Sciences Biotechnology and R&D practice.  As a former Partner and practice leader with Ernst & Young LLP, he acted as a strategic advisor to leading-edge companies in life sciences and high technology over a period of 17 years.  Matthew was a founding management team member of three start-up companies, one of which had a successful IPO and was subsequently acquired. The other two were successfully acquired by larger companies.




Faming Zhang
Chairman
Waterstone Pharmaceuticals Inc.

12202 Hancock St,
Carmel, INa 46032 
(317) 644-0862                                                
www.waterstonetech.com

Dr. Zhang is currently President, Crown Biosciences, a leading preclinical biology CRO company. He is also the co-founder of Kinasia Biopharmaceuticals, Inc. and Chairman of  Waterstone Pharmaceuticals.  Dr. Zhang had 12 years Pharmaceutical industry experience from Eli Lilly and Company. He had served as Global Head of Drug Discovery and Development Information Sciences at Lilly. Prior to the management role, he was a senior research scientist at Lilly leading the structure-based drug design group.

Dr. Zhang received his Ph.D in Biochemistry and Molecular Biology from Institute of Biophysics, Chinese Academy of Sciences and MBA from Kelly business school of Indiana University. Prior to join Eli Lilly and Company, he had a 4 year postdoctoral training from University of Texas Southwestern Medical Center in Dallas. He is also an associate professor of Chemistry and Biochemistry program at Indiana University. Dr. Zhang has authored more than 30 scientific publications including 2 Nature articles and was the co-inventor of sever patents in the area of anti-cancer and novel anti-obesity protein therapeutics




Dick Aderman
President & COO
Quadraspec

3000 Kent Ave.
West Lafayette, IN 47906
(765) 775-1026
www.quadraspec.com

Dick Aderman has an extensive background in diagnostics and healthcare. From 1980 through 1996 he held various positions in sales, marketing and general management with American Hospital Supply Corporation, Baxter Healthcare and Dade International. Nearly all his time there was in the laboratory diagnostics business where he established a track record of successful results with product line turnarounds, new product launches and product line growth strategies.

From 1997 through mid-2005, Dick was a member of senior management at Boehringer Mannheim later acquired by Roche Diagnostics. There he lead in the explosive growth of Roche through his leadership in Corporate Accounts, amassing an impressive record of successful contract negotiations  in GPO’s and IHN’s resulting in double digit growth for Roche Diagnostics.

He was appointed to Sr. VP and GM for the Centralized and Molecular Lab businesses in 2000. Here he led his team to a dramatic turned around through the implementation of a strong vision and the implementation of five key strategies. Amongst those, was the implementation of a focused customer marketing method, Six Sigma for process excellence, the Roche customer experience, the leadership through employee enrichment and innovation for growth. These actions resulted in annual sales growth of over 11% and annual profit growth of over 65% during a 5 year period. 

During this time period, Roche Diagnostics became the number one diagnostics company in the U.S. and achieved the top ranking in customer satisfaction. Roche also was named to the Top 100 Best Places to Work list by Fortune Magazine. They were also recognized by Frost and Sullivan as the leader for innovation with on-line services and connectivity solutions for customers.

From mid-2005 until present, Dick has been involved with early and mid-stage start-ups in disease management software, medical devices and marketing consulting. He joined Quadraspec’s Board of Directors in December of 2006 and joined the executive leadership team as President and Chief Operating Officer in September of 2007.

Dick lives in Carmel, Indiana with his wife and two teenage daughters. He also serves as Chairman of the Board for the American Heart Association of Indianapolis.

He is a 1979 graduate of Western Michigan University in Kalamazoo, MI where he earned degrees in business administration (BBA) and speech communications (BS).




William Ringo
Senior Vice President, Strategy and Business Development
Pfizer Inc

235 East 42nd Street
MS 235/23/2
New York, NY 10017
www.pfizer.com

Bill Ringo is the Senior Vice President of Strategy and Business Development at Pfizer, with responsibility for guiding the company’s overall strategic planning and business development activities. 

Prior to joining Pfizer in April 2008, Bill served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From 2004 to 2006, he was President and CEO of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which purchased Abgenix in 2006.

From 2001 to 2004, he served on various boards – including the board of Encysive Pharmaceuticals, which Pfizer recently acquired – and was associated with Intermune, where he was appointed interim chief executive officer to help restructure the company and recruit new operational leadership.

Bill began his career at Eli Lilly & Company in 1973 and during his 28-year tenure there he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001.
Bill – who holds a B.S. in Business Administration and an M.B.A. form the University